. 2010 Dec 8;2(2):171–176. doi: 10.1021/ml100251u

Table 4. In Vitro and in Vivo Potencies of 39, 41, and Nicotinic Acid.

	39	41	nicotinic acid
hu-GPR109a EC₅₀ (nM)^a	59 ± 56	49 ± 11	100 ± 15
rat-GPR109a EC₅₀ (nM)^a	3 ± 1	6 ± 2	39 ± 10
m-GPR109a EC₅₀ (nM)^a	4 ± 3	15 ± 5	29 ± 5
dog-GPR109a EC₅₀ (nM)^a	21 ± 4	126 ± 58	30 ± 14
cyno-GPR109a (nM)^a	2 ± 1	nd^b	26 ± 33
hu-GPR109b EC₅₀ (nM)^a	300 ± 105	1120 ± 325	>10000
rat FFA reduction (1 h post 1 mg/kg dosing)	−77%	−14%	−80%^c
rat TG reduction (1 h post 1 mg/kg dosing)	−49%	−23%	−60%^c
dog FFA reduction (1 h post 3 mg/kg dosing)	−70%	nd^b	−38%

Data represent an average of multiple determinations (n ≥ 3) ± standard deviation.

nd = not determined.

10 mg/kg dosing.